Cargando…

Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve

BACKGROUND: Coronary artery disease and aortic stenosis often coexist. Transcatheter aortic valve implantation (TAVI) has emerged as a valid therapeutic option for younger, lower-risk patients who may eventually require coronary artery disease treatment. Thus, post-TAVI coronary access (CA) and perc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarantini, Giuseppe, Nai Fovino, Luca, Le Prince, Pascal, Darremont, Olivier, Urena, Marina, Bartorelli, Antonio L., Vincent, Flavien, Hovorka, Tomas, Alcalá Navarro, Yasmina, Dumonteil, Nicolas, Ohlmann, Patrick, Wendler, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373469/
https://www.ncbi.nlm.nih.gov/pubmed/32580586
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.008972
_version_ 1783561498888503296
author Tarantini, Giuseppe
Nai Fovino, Luca
Le Prince, Pascal
Darremont, Olivier
Urena, Marina
Bartorelli, Antonio L.
Vincent, Flavien
Hovorka, Tomas
Alcalá Navarro, Yasmina
Dumonteil, Nicolas
Ohlmann, Patrick
Wendler, Olaf
author_facet Tarantini, Giuseppe
Nai Fovino, Luca
Le Prince, Pascal
Darremont, Olivier
Urena, Marina
Bartorelli, Antonio L.
Vincent, Flavien
Hovorka, Tomas
Alcalá Navarro, Yasmina
Dumonteil, Nicolas
Ohlmann, Patrick
Wendler, Olaf
author_sort Tarantini, Giuseppe
collection PubMed
description BACKGROUND: Coronary artery disease and aortic stenosis often coexist. Transcatheter aortic valve implantation (TAVI) has emerged as a valid therapeutic option for younger, lower-risk patients who may eventually require coronary artery disease treatment. Thus, post-TAVI coronary access (CA) and percutaneous coronary intervention are expected to increase. The purpose of this study was to retrospectively evaluate patients who were enrolled in the SOURCE 3 (SAPIEN 3 Aortic Bioprosthesis European Outcome) European registry for treatment with the balloon-expandable SAPIEN 3 transcatheter heart valve and underwent CA with or without percutaneous coronary intervention after TAVI. METHODS: Baseline characteristics and clinical outcomes of patients with or without CA up to 3 years after TAVI were compared. A Kaplan-Meier estimate with a univariate model determined the impact of CA on cardiac mortality. RESULTS: Of 1936 TAVI patients (mean age 81.6 years, 52% male), 68 (3.5%) had CA within 3 years (mean 441±332 days) after TAVI. At baseline, the logistic EuroSCORE was similar (20.2% versus 18.3%, P=0.2, CA and non-CA groups, respectively). Higher rates of coronary artery disease (76.5% versus 50.6%, P<0.001), myocardial infarction (20.6% versus 11.5%, P=0.03) and previous coronary artery bypass graft (22.1% versus 11.0%, P=0.01) were present in the CA group. In 100% of patients, CA was successfully achieved. The clinical success of percutaneous coronary intervention was 97.9%. Cardiovascular mortality was numerically higher in patients with CA than in those without CA. CONCLUSIONS: In the large SOURCE 3 European registry, CA was needed at 3-year follow-up after TAVI with a balloon-expandable valve in 3.5% of patients and was successful in all patients. The clinical success of percutaneous coronary intervention was 97.9%. REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02698956.
format Online
Article
Text
id pubmed-7373469
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-73734692020-08-05 Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve Tarantini, Giuseppe Nai Fovino, Luca Le Prince, Pascal Darremont, Olivier Urena, Marina Bartorelli, Antonio L. Vincent, Flavien Hovorka, Tomas Alcalá Navarro, Yasmina Dumonteil, Nicolas Ohlmann, Patrick Wendler, Olaf Circ Cardiovasc Interv Original Articles BACKGROUND: Coronary artery disease and aortic stenosis often coexist. Transcatheter aortic valve implantation (TAVI) has emerged as a valid therapeutic option for younger, lower-risk patients who may eventually require coronary artery disease treatment. Thus, post-TAVI coronary access (CA) and percutaneous coronary intervention are expected to increase. The purpose of this study was to retrospectively evaluate patients who were enrolled in the SOURCE 3 (SAPIEN 3 Aortic Bioprosthesis European Outcome) European registry for treatment with the balloon-expandable SAPIEN 3 transcatheter heart valve and underwent CA with or without percutaneous coronary intervention after TAVI. METHODS: Baseline characteristics and clinical outcomes of patients with or without CA up to 3 years after TAVI were compared. A Kaplan-Meier estimate with a univariate model determined the impact of CA on cardiac mortality. RESULTS: Of 1936 TAVI patients (mean age 81.6 years, 52% male), 68 (3.5%) had CA within 3 years (mean 441±332 days) after TAVI. At baseline, the logistic EuroSCORE was similar (20.2% versus 18.3%, P=0.2, CA and non-CA groups, respectively). Higher rates of coronary artery disease (76.5% versus 50.6%, P<0.001), myocardial infarction (20.6% versus 11.5%, P=0.03) and previous coronary artery bypass graft (22.1% versus 11.0%, P=0.01) were present in the CA group. In 100% of patients, CA was successfully achieved. The clinical success of percutaneous coronary intervention was 97.9%. Cardiovascular mortality was numerically higher in patients with CA than in those without CA. CONCLUSIONS: In the large SOURCE 3 European registry, CA was needed at 3-year follow-up after TAVI with a balloon-expandable valve in 3.5% of patients and was successful in all patients. The clinical success of percutaneous coronary intervention was 97.9%. REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02698956. Lippincott Williams & Wilkins 2020-06-25 /pmc/articles/PMC7373469/ /pubmed/32580586 http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.008972 Text en © 2020 The Authors. Circulation: Cardiovascular Interventions is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
spellingShingle Original Articles
Tarantini, Giuseppe
Nai Fovino, Luca
Le Prince, Pascal
Darremont, Olivier
Urena, Marina
Bartorelli, Antonio L.
Vincent, Flavien
Hovorka, Tomas
Alcalá Navarro, Yasmina
Dumonteil, Nicolas
Ohlmann, Patrick
Wendler, Olaf
Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve
title Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve
title_full Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve
title_fullStr Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve
title_full_unstemmed Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve
title_short Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve
title_sort coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373469/
https://www.ncbi.nlm.nih.gov/pubmed/32580586
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.008972
work_keys_str_mv AT tarantinigiuseppe coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT naifovinoluca coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT leprincepascal coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT darremontolivier coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT urenamarina coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT bartorelliantoniol coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT vincentflavien coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT hovorkatomas coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT alcalanavarroyasmina coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT dumonteilnicolas coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT ohlmannpatrick coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve
AT wendlerolaf coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve